Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cancer Gene Ther. 2012 Apr 20;19(7):443–450. doi: 10.1038/cgt.2012.14

Figure 4. VSV-IFN therapeutic efficacy in mice bearing orthotopic myeloma.

Figure 4

5TGM1 cells were implanted IV in syngeneic C57Bl/KalWrij mice. (A) Mean serum IgG2b concentration was quantified at 7 day intervals (n=26 mice). Mean serum IgG2b was measured by ELISA and compared using a t-test indicating a significant change in serum IgG2b from day 14 to day 21 post 5TGM1 implantation (*P=0.0019) (B) Survival response in myeloma bearing mice following a single IV dose of PBS, or 1×108 VSV-mIFNβ or VSV-hIFNβ. Survival was compared by log-rank analysis. VSV-mIFNβ and VSV-hIFNβ treatment significantly prolonged survival compared to PBS (P=0.0008*** and P=0.017* respectively), and survival of mice treated with VSV-mIFNβ is significantly prolonged compared to VSV-hIFNβ treated mice (P=0.021*) (C) Myeloma burden in response to IV treatment with PBS, VSV-mIFNβ or VSV-hIFNβ measured by serum IgG2b ELISA.